ZAGAMI, PAOLA
ZAGAMI, PAOLA
Dipartimento di Oncologia ed Emato-Oncologia
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
2025 B. Taurelli Salimbeni, F. Giudici, C. Pescia, P.P.M. Berton Giachetti, R. Scafetta, P. Zagami, A. Marra, D. Trapani, A. Esposito, S. Scagnoli, B. Cerbelli, A. Botticelli, E. Munzone, N. Fusco, C. Criscitiello, G. Curigliano
Understanding metastasis mixed-treatment responses through genomic analyses
2025 S. Garcia-Recio, P. Zagami, B.M. Felsheim, A. Wheless, K. Thomas, R. Trimarchi, L.A. Carey, C.M. Perou
Spectral CT for non-invasive evaluation of bladder cancer grade
2025 R. Trimarchi, N. Migliaccio, G.M. Bucolo, C. Abate, F.M. Aricò, V. Ascenti, A. Portaluri, M. Rossanese, P. Zagami, T. D'Angelo, F. Piacentino, M. Venturini, G. Ascenti
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
2025 P. Zagami, A. Esposito, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, R. Scafetta, M. Lambertini, M. Di Maio, G. Curigliano, C. Criscitiello, S. Cinieri
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer
2025 K.M. Boehm, O.S.M. El Nahhas, A. Marra, M. Waters, J. Jee, L. Braunstein, N. Schultz, P. Selenica, H.Y. Wen, B. Weigelt, E.D. Paul, P. Cekan, R. Erber, C.M.L. Loeffler, E. Guerini-Rocco, N. Fusco, C. Frascarelli, E. Mane, E. Munzone, S. Dellapasqua, P. Zagami, G. Curigliano, P. Razavi, J.S. Reis-Filho, F. Pareja, S. Chandarlapaty, S.P. Shah, J.N. Kather
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
2025 R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano, L. Guidi, D. Izzo, P. Zagami, D. Trapani, G. Curigliano
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
2025 R. Scafetta, P. Zagami, M. Del Re, C. Criscitiello, A. Marra, G. Curigliano
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Molecular tumour board in gastrointestinal cancers
2025 L. Boscolo Bielo, E. Crimini, M. Repetto, M. Barberis, E. Battaiotto, J. Katrini, E. Martino, G. Gaudio, M. Lombardi, C. Zanzottera, G. Aurilio, C. Belli, Y. Zhan, V. Fuorivia, R.M. Marsicano, J.D. Etessami, P. Zagami, A. Marra, D. Trapani, B. Taurelli Salimbeni, C. Criscitiello, D. Ciardiello, B. Lavinia, L. Gervaso, C.A. Cella, F. Spada, M.G. Zampino, N. Fusco, N. Fazio, E. Guerini Rocco, G. Curigliano
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 G. Antonarelli, M. Milano, C. Andreon, S. Gandini, G. Pellizzari, D. Trapani, S. Dellapasqua, A. Marra, P. Zagami, C. Valenza, M. Colleoni, E. Munzone, G. Curigliano
Comprehensive Diagnostic and Therapeutic Approaches for Estrogen Receptor-Low Breast Cancer: A Multidisciplinary Perspective From Oncologists and Pathologists
2025 P. Zagami, A. Botticelli, I. Castellano, G. Curigliano, G. D'Amati, C. De Angelis, M.V. Dieci, V. Errigo, A. Fabi, M. Lambertini, A. Rizzo, A. Santinelli, A. Sapino, C. Scatena, C. Criscitiello, N. Fusco
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2024 S. Alaklabi, A. Mariam Roy, P. Zagami, A. Chakraborty, N. Held, J. Elijah, A. George, K. Attwood, S.S. Shaikh, L.N. Chaudhary, Y. Abdou, S. Gandhi
High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond
2024 A. Edsjo, H.G. Russnes, J. Lehtio, D. Tamborero, E. Hovig, A. Stenzinger, R. Rosenquist, A. Janowska, A.L. Rioja, A. Stenzinger, A. Razzak, A. Edsjo, A. Lepland, A. Marra, A. Planken, A. Helland, A. Patocs, B. Mainoli, B. Ryll, B. Brasiuniene, D. Kazdal, D. Tamborero, D. Cerina, E.H. Hult, E. Baltruskeviciene, E. Vrdoljak, E. Hovig, E. Chavarria, E. Garralda, E. Aas, E. Bjorgo, E. Voest, G. Curigliano, G.L. Fagereng, H. Gelderblom, H.G. Russnes, H. Verheul, H. Timmer, I. Brana, I. Lugowska, J. Lehtio, J.-. Blay, J. Oliveira, K. Rekker, K. Toome, K. Jalkanen, K. Tasken, K. Smeland, K. Ojamaa, K.S. Rohrberg, L. Verlingue, M. Antouly, M. Mustonen, P. Zagami, P. Nagy, P. Nygren, P. Asplund, R. Sabaliauskaite, R. Rosenquist, R. Henrique, S.B. van Waalwijk van Doorn-Khosrovani, S. Brabrand, S. Ekman, S.H. Mohammad, S. Jarmalaite, T. Juslin, T. Kahre, T. Kringelbach, T. Guren, U. Lassen, V.K. Grolmusz, X.V. Alberu
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
2024 A. Fernandez-Martinez, M. Tanioka, S.G. Ahn, P. Zagami, T. Pascual, M. Rediti, G. Tang, K.A. Hoadley, D. Venet, N.U. Rashid, P.A. Spears, S. Di Cosimo, E. De Azambuja, A. Choudhury, P. Rastogi, M.N. Islam, J. Cortes, A. Llombart-Cussac, S.M. Swain, C. Sotiriou, A. Prat, C.M. Perou, L.A. Carey
UNDERSTANDING METASTASIS MIXED - TREATMENT RESPONSES THROUGH GENOMIC ANALYSES.
2024 P. Zagami
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
2024 E. Nicolò, S. Gandini, F. Giugliano, J. Uliano, O. D'Ecclesiis, S. Morganti, E. Ferraro, D. Trapani, P. Tarantino, P. Zagami, L. Boldrini, I. Caramella, A. Carnevale Schianca, M. Cristofanilli, M.A. Locatelli, A. Esposito, C. Belli, I. Minchella, C. Criscitiello, A. Marra, G. Curigliano
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
2024 C. Valenza, D. Trapani, P. Zagami, G. Antonarelli, L. Boscolo Bielo, E. Nicolò, J.M. Ribeiro, L. Guidi, C. Reduzzi, M. Spotti, L. Adamoli, J. Cortès, B. Pistilli, S.M. Tolaney, N. Ueno, R.M. Layman, M. Cristofanilli, L.A. Carey, E. Munzone, C. Criscitiello, F. Lynce, W.A. Woodward, G. Curigliano
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives
2024 L. Ascione, G. Castellano, G. Curigliano, P. Zagami